Business context and reporting period
Regencell Bioscience Holdings Limited filed an annual Form 20-F for the fiscal year ended June 30, 2021, with comparative results for fiscal 2020 and 2019. The supplied period label “2020 Q4” does not match the filing’s annual reporting period. Figures below are in U.S. dollars unless stated otherwise.
The Hong Kong-based early-stage bioscience company is developing Traditional Chinese Medicine (TCM) products, primarily for ADHD and autism spectrum disorder (ASD). It had no product revenue and remained in research and development. Its shares began trading on Nasdaq under RGC in July 2021.
Financial highlights
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $1.381 million | $812,371 |
| Net loss | $1.347 million | $812,371 |
| Loss per share, basic and diluted | $0.13 | $0.08 |
| Cash used in operating activities | $767,311 | $726,573 |
| Cash at year-end | $59,413 | $386,979 |
| Total assets | $340,134 | $514,018 |
| Total liabilities | $4.338 million | $3.165 million |
| Shareholders’ deficit | $3.998 million | $2.651 million |
No gross margin or operating margin is meaningful because the company reported no revenue. FY2021 operating expenses rose 70%: general and administrative expense increased to $941,463 from $311,934, and R&D expense rose to $438,323 from $386,230; selling and marketing expense declined to $1,576 from $114,207. Other income of $34,617 in FY2021 was primarily a Hong Kong government COVID-related subsidy.
At June 30, 2021, current assets were $66,849 against current liabilities of $4.338 million. The balance sheet included $431,969 in shareholder loans and a $3.25 million interest-free convertible note payable to CEO Yat-Gai Au, alongside accrued expenses and related-party payables. The filing reports no material off-balance-sheet arrangements. Operating lease commitments totaled $1.281 million.
Material changes versus the prior comparable period
- Net loss widened by about 66%, from $812,371 to $1.347 million, mainly as general and administrative costs increased.
- Operating cash outflow increased modestly, while year-end cash fell by $327,566.
- FY2021 financing cash flow was $439,745, primarily from shareholder loans, compared with $988,082 in FY2020.
- The $3.25 million shareholder-loan conversion note was converted into 342,105 shares at $9.50 per share upon the July 2021 IPO; the remaining shareholder-loan balance was reported settled with IPO proceeds in August 2021.
Outlook, commentary, risks and unusual items
- Management expects continued losses and higher R&D, staffing, public-company and commercialization costs. There is no revenue or earnings guidance, and the filing gives no assured timetable for product approval or sales.
- The company completed a first uncontrolled study involving seven patients; it reported preliminary improvements based largely on caregiver assessments. The filing cautions that the study was small, uncontrolled, and potentially subject to reporting bias. A second study using three standardized formula candidates began in Q3 2021, with a planned target of 100 patients and treatment lasting three to twelve months.
- No product candidate had regulatory approval, and the company had not applied for approval. Commercialization depends on further research, safety and quality testing, Hong Kong licensing and product registration, and manufacturing and distribution capabilities that the company had not yet established.
- The company disclosed recurring losses, negative operating cash flows, and substantial doubt about its ability to continue as a going concern based on conditions at year-end. Management said the subsequent IPO and debt conversion materially improved its ability to fund operations for at least one year after issuance of the financial statements. IPO and over-allotment proceeds were approximately $24.94 million gross; reported net proceeds were approximately $19.82 million plus approximately $2.85 million from the over-allotment.
- A September 2021 joint venture with Honor Epic was formed to pursue COVID-related TCM products in designated Asian-Pacific markets. Regencell’s subsidiary is to fund 60% and receive 60% of profits or losses; commercialization and the treatment research remain uncertain. The company cited treatment observations from 12 suspected or confirmed COVID cases, not controlled clinical evidence.
- The auditor issued an unqualified opinion on the financial statements. Management nevertheless concluded that internal control over financial reporting was ineffective at June 30, 2021, citing two material weaknesses: insufficient U.S. GAAP/SEC reporting expertise and formal procedures, and no internal audit function. Remediation was ongoing.
- Other significant exposures include dependence on the CEO and the CEO’s father, who is the strategic TCM practitioner; related-party funding and arrangements; uncertain intellectual-property protection; Hong Kong political and regulatory developments; COVID-related research disruption; and potential dilution from share options. The filing reports no pending material legal proceedings.
Important facts for investors to verify
- Confirm the fiscal-year period and distinguish the June 30, 2021 audited results from subsequent IPO, debt-conversion and joint-venture events.
- Review the full audited statements and related-party notes, including the year-end loan, convertible-note and accrued-liability balances and their subsequent settlement.
- Track cash use, IPO-proceeds deployment, lease and renovation commitments, and the company’s runway against planned R&D and hiring.
- Assess the design, enrollment, controls and results of the second ADHD/ASD study, and the evidence and regulatory pathway for the COVID-related TCM treatment.
- Monitor regulatory applications, manufacturing readiness, intellectual-property filings, and progress remediating the disclosed material weaknesses.